Rakuten Medical, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 101
- Market Cap
- -
A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
Cancer Clinic, Lexington, Kentucky, United States
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05265013
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Rakuten Medical, Inc.
- Registration Number
- NCT05220748
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05182866
- Locations
- 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04305795
- Locations
- 🇺🇸
University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸Providence Medical Center, Portland, Oregon, United States
🇺🇸University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT03769506
- Locations
- 🇨🇳
Cancer Clinic, Taoyuan, Taiwan
🇺🇸Cancer Clinic 1, Philadelphia, Pennsylvania, United States
🇺🇸Cancer Clinic 2, Philadelphia, Pennsylvania, United States
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02422979
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Rush University Cancer Center, Chicago, Illinois, United States
🇺🇸University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States